Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab after recent acute coronary syndrome
NL-OMON45085Phase 3Active, not recruiting
- Sponsor
- Sanofi
- Start
- Jul 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in acute coronary syndrome (ACS) and hypercholesterolemia comparing Alirocumab with Placebo (2 arms). Primary endpoint: Time to first major cardiovascular event. Started Jul 2013; status: active, not recruiting.
02
Drugs
alirocumab
03
Conditions
acute coronary syndrome (ACS)hypercholesterolemia
Beyond the preview
Go deeper on NL-OMON45085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45085.